Insulet Corporation (PODD)

3 members of Congress have disclosed trading PODD — 2 purchases and 3 sales worth an estimated $40,000. Most recent disclosure: Feb 16, 2021.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Company website ↗

• P/E ratio (36.9) — how many dollars you pay for each $1 of PODD's yearly profit. That's a fairly normal range.
• ROE (23.00%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
• Profit margin (10.44%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend — PODD doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.